IgG4-RD was first recognized as a disease in the early 2000’s and can be difficult to diagnose. While the exact cause is unknown, doctors believe an overactive immune system leads to inflammation, which can damage various organs, including the liver and kidneys. Symptoms can vary from person to person and can include fatigue, weight loss, dry eyes, and headaches.* FDA-approved treatment can help manage the disease and reduce flares.
*These are common symptoms of IgG4-RD, which may occur at the same time. Having these symptoms does not confirm a diagnosis of IgG4-RD.
87% decrease in IgG4-RD flare risk
In a 52-week patient study, 7 out of 68 patients taking UPLIZNA had IgG4-RD flares compared to 40 out of 67 patients on placebo.†
UPLIZNA is given twice a year after 2 startup doses, 2 weeks apart, then 1 infusion every 6 months
It can be administered in an infusion center, hospital, doctor’s office, or possibly in your home.
Safety was evaluated in the first IgG4-RD phase 3 study done on patients, leading to FDA approval
Most common side effects include COVID-19, urinary tract infection, and low white-blood cell count.
*Placebo is a substance that has no medicinal effect and is often used as a comparison in testing drugs.
FDA, Food and Drug Administration; IgG4-RD, immunoglobulin G4-related disease.
Steroids help reduce inflammation but can cause side effects with long-term use. Unlike steroids, UPLIZNA targets immune cells linked to IgG4-RD and flares.
